Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TPST Tempest Therapeutics

Watchlist
2.410
+0.100+4.33%
Close 06/24 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
2.420
Open
2.385
Turnover
107.40K
Low
2.219
Pre Close
2.310
Volume
46.01K
Market Cap
24.88M
P/E(TTM)
1.27
52wk High
41.000
Shares
10.32M
P/E(Static)
Loss
52wk Low
2.000
Float Cap
13.74M
Bid/Ask %
-33.33%
Historical High
260.100
Shs Float
5.70M
Volume Ratio
1.09
Historical Low
2.000
Dividend TTM
--
Div Yield TTM
--
P/B
0.85
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.81%
Amplitude
8.70%
Avg Price
2.334
Lot Size
1
Float Cap
13.74M
Bid/Ask %
-33.33%
Historical High
260.100
Shs Float
5.70M
Volume Ratio
1.09
Historical Low
2.000
Dividend TTM
--
P/B
0.85
Dividend LFY
--
Turnover Ratio
0.81%
Amplitude
8.70%
Avg Price
2.334
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
CEO: Brady J.D., LLM, Stephen R.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top